Navigating the Evolving Treatment Landscape in mCRPC - European Medical Journal

Continue

Navigating the Evolving Treatment Landscape in mCRPC

Urology

This is a non-promotional medical symposium funded and organised by Bayer.

This presentation contains information on products, indications or combinations that are not licensed in all countries, or not licensed in any region. Please consult your local prescribing information for more information. This content is intended for healthcare professionals only.

The Bayer sponsored symposium, titled ‘Navigating the Evolving Treatment Landscape in mCRPC’, took place on 21 March 2025 at the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain. Three expert faculty, Martin Bögemann, Pedro Barata, and Alejo Rodriguez-Vida, came together to discuss the latest data and changing treatment paradigm within mCRPC. 

The program commenced with an introduction by Bögemann, who provided an overview of the unmet medical needs and the current treatment landscape and its limitations for patients with mCRPC. Following this introduction, Barata presented data on new combination approaches and recent clinical developments with the potential to reshape the treatment of patients with mCRPC. As Barata concluded his presentation, Rodriguez-Vida took the opportunity to discuss treatments on the horizon, offering insights into the future direction of mCRPC management. Following these presentations, the symposium concluded with a panel Q&A session where the expert faculty had the opportunity to provide additional insights on the path forward in the management of mCRPC.

Speakers

Martin Bögemann1

 

Pedro Barata2

 

Alejo Rodriguez-Vida3

 

1. Head of the Uro-Oncology Section, Department of Urology, University Hospital of Münster, Germany
2. Medical Oncologist, Director of Clinical Research of GU Medical Oncology Research Programme, and Co-Leader of the Genitourinary (GU) Disease Team, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA
3. GU Medical Oncologist, Hospital del Mar, Barcelona, Spain


PP-UN-ONC-ALL-0023-1

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.